Advancements in Glucose Monitoring

Slides:

Advertisements

Similar presentations

Monitoring diabetes Diabetes Outreach (March 2011)

Advertisements

Past, Present and the Future Rabin Mohanty Consultant Paediatrician Blackpool.

A Day in the Life of a Type 2 Diabetic

Diabetes Technology Update

Prevention of Type 2 Diabetes. Hyperglycemia in Type 2 Diabetes: Changing Treatment Paradigms.

RtII for Middle School Bethann M. McCain; RtII Consultant

Scientific Method. Ask a question Ask a question.

Think of two characters in Of Mice and Men who affect the outcome of the story. Discuss the actions and interactions of each character. Also, discuss how.

Feedback Why is it that a higher level of system organization is more stable? Definition of a system: keyword interact If one part has an effect on the.

LCR PCT Dave Briggs – Clinical Lead Tim Sacks – PBC Management Lead

Accountability to Affected Populations 8 December 2015.

Dr Zaranyika MBChB(Hons) UZ, MPH, FCP SA Department of Medicine UZ-CHS

1 Establishment of Blood Glucose Monitoring System Using the Internet Diabetes Care 27:478–483, 2004 Long-Term effect of the Internet-Based Glucose Monitoring.

What's New in Basal Insulin for Diabetes

Fig. 2. Change in (A) glycosylated hemoglobin (HbA1c) and (B) fasting plasma glucose (FPG). Group A: oral hypoglycemic agents (OHAs; sulfonylurea+metformin.

Estephanie Olivares, HHSD Program Coordinator

Monitoring & Evaluation Processes A A walkthrough of the whole process

Feedback Why is it that a higher level of system organization is more stable? Definition of a system: keyword interact If one part has an effect on the.

Dr Adhya Mehta Department of Medicine

Type 1 Diabetes: Meters, Pumps, and Transitions to Adulthood

Short-, Intermediate-, Long-Acting Insulins

Diabetic Dyslipidemia in Practice

Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.

نتعارف لنتألف في التعارف تألف (( الأرواح جنود مجندة , ماتعارف منها أئتلف , وماتنافر منها اختلف )) نماذج من العبارات الايجابية.

Diabetes and Risk of CV Outcomes

Lifestyle and Professional CGM

Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.

Using the AGP to Standardize Glucose Reporting

New Patient-Friendly Options for Managing Insulin Dosing

Updates Abound.

Best Practices in Advanced Glucose Monitoring

Examining CV Effects of Basal Insulin Therapy

Updates to Managing Diabetes in the Long-Term Care Setting

Monitoring in Type 2 Diabetes

Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?

Sequential insulin strategies in type 2 diabetes.

Faster-Acting Insulins

Statins and Glucose Metabolism: Are All Agents Alike?

Integrated Diabetes Care: How Can We Make the Best Use of New Technology?

Insulin Use in Primary Care: Practice Challenges

Continuous glucose monitoring tracings of two patients with type 1 diabetes (one patient per panel) on a day when aerobic exercise was performed (open.

Simplifying Insulin Delivery for Better Patient Outcomes in T2D

Predictive Low Glucose Suspend (PLGS)

The Primary Care Guide to New CGM Devices and the AGP

Glucose Monitoring: An Evolving Landscape

T2DM Management.

Better Diabetes Control With Novel Basal Insulins

Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?

Modern Advances in Glucose Monitoring

Behavioral Assessment: Initial Considerations

Younger Patients With Type 1 Diabetes: Can We Optimize Their Insulin Therapy?

The Role of the Kidney in Glucose Control

Evaluating Expressions

Hypoglycemia: The Most Common Barrier to Effective Diabetes Management

Statins, Obesity, and Hyperlipidemia

Glucose Management and Statin Therapy

NP and PA Expert Exchange:

Patient flow chart: the final prospective study population consisted of 521 individuals, 113 on basal insulin and 408 on OADs. *Plausibility: height (130–230 cm),

Improving Effective Basal Insulin Use in Clinical Practice

Group Behavior.

IMPACT OF PHARMACIST DELIVERED CARE IN THE COMMUNITY PHARMACY SETTING

Glucose Management and Statin Therapy

Ethical Decision Making

Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.

Changing Education Paradigms

Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.

The Expanding Role of SGLT Inhibitors Across the Diabetes Spectrum

Fresh perspectives ON BASAL Insulins in diabetes care

Nutrition Interventions to Improve Quality of Care

The Challenge of Insulin Titration

Presentation transcript:

Rewriting the Code Advances in Glucose Data Interpretation and Impact on Clinical Decision-Making

Advancements in Glucose Monitoring

The Role of Glucose Data

The AGP Report 14 Days of Glucose Data

Why the Need for the AGP Report

HbA1c Does Not Tell the Whole Story

Case Study: Type 1 Diabetes Longitudinal Evaluation With Intervention

Consultation #1 Reduce Variability: Behavioral Changes

Consultation #2 Increase Stability: Target Basal Insulin

Consultation #3 Improve Exposure: Reinforce, Adjust Insulin

Conclusions

Abbreviations